– Phase 3 Programs Underway in Uterine Fibroids and Assisted Reproduction Technology (ART) – Geneva, Switzerland and Boston, MA – May 18, 2017 – ObsEva SA (NASDAQ:…
Tag: 2017
ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor – Geneva, Switzerland and Boston, MA – 18…
ObsEva SA to Attend BioEquity Europe 2017 in Paris
Geneva, Switzerland – 16 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
Geneva, Switzerland and Boston, MA – May 11, 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Q1 2017 ObsEva SA Earnings Conference Call
ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids
– PRIMROSE 1 and PRIMROSE 2, pivotal Phase 3 clinical trials to assess efficacy and safety of novel oral GnRH…
ObsEva SA at the Needham Annual Healthcare Conference
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
Geneva, Switzerland – 24 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist – Geneva, Switzerland – 17 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company…
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
– IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer…